Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases

Case report: The effective response to pembrolizumab in combination with bevacizumab in the treatment of a recurrent glioblastoma with multiple extracranial metastases

Multiple extracranial metastases of recurrent glioblastoma are rare and often indicate a very poor prognosis. The main conventional treatments are chemotherapy, radiotherapy, chemoradiotherapy or antiangiogenic therapy. Median overall survival is 2.3 to 6 months after the detection of extracranial m...

Full description

Bibliographic Details
Main Authors: Gang Yang, Yu Fang, Ming Zhou, Wei Li, Dapeng Dong, Jing Chen, Yong Da, Kunpeng Wang, Xinru Li, Xiaoyan Zhang, Tonghui Ma, Ge Shen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
extracranial metastases glioblastoma
bevacizumab
pembrolizumab
combined treatment
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.948933/full

Similar Items

Similar Items